All In Biotech

Drug Trial Radar · NCT04586231

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 747 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

747

Actual

Start

Feb 25, 2021

Primary completion

Feb 2, 2026

Study completion Feb 11, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Eisai Inc.
First posted
Oct 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.

Conditions

  • Carcinoma, Renal Cell

Interventions

  • BelzutifanDrug

    Oral administration

  • LenvatinibDrug

    Oral administration

  • CabozantinibDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 34 months
  2. Overall Survival (OS)Time frame: Up to approximately 44 months

Locations

184 sites in 25 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer & Research Centers ( Site 0077)

    Chandler, Arizona

  • Cedars Sinai Medical Center ( Site 0027)

    Los Angeles, California

  • UCLA Hematology/Oncology - Santa Monica ( Site 0048)

    Los Angeles, California

  • St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0095)

    Orange, California

  • University of California, Irvine ( Site 0029)

    Orange, California

  • Providence Saint John's Health Center ( Site 0083)

    Santa Monica, California

  • Georgetown University Medical Center ( Site 0006)

    Washington D.C., District of Columbia

  • AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0003)

    Orlando, Florida

  • Orlando Health, Inc. ( Site 0035)

    Orlando, Florida

  • University Cancer & Blood Center, LLC ( Site 0057)

    Athens, Georgia

  • Emory University Hospital ( Site 0012)

    Atlanta, Georgia

  • Rush University Medical Center ( Site 0040)

    Chicago, Illinois

  • Illinois Cancer Care, PC ( Site 0008)

    Peoria, Illinois

  • Parkview Cancer Institute ( Site 0088)

    Fort Wayne, Indiana

  • Norton Cancer Institute - St. Matthews ( Site 0065)

    Louisville, Kentucky

  • Tulane University School of Medicine ( Site 0098)

    New Orleans, Louisiana

  • Lahey Hospital & Medical Center ( Site 0090)

    Burlington, Massachusetts

  • Cancer & Hematology Centers of Western Michigan ( Site 0018)

    Grand Rapids, Michigan

  • HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0005)

    Saint Louis Park, Minnesota

  • University of Mississippi Medical Ctr ( Site 0037)

    Jackson, Mississippi

  • Cancer Partners of Nebraska ( Site 0086)

    Lincoln, Nebraska

  • Rutgers Cancer Institute of New Jersey ( Site 0078)

    New Brunswick, New Jersey

  • R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0013)

    Lake Success, New York

  • Memorial Sloan Kettering Cancer Center ( Site 0055)

    New York, New York

  • Levine Cancer Institute ( Site 0004)

    Charlotte, North Carolina

  • Duke Cancer Institute ( Site 0096)

    Durham, North Carolina

  • Lehigh Valley Hospital- Cedar Crest-Oncology Clinical Trials ( Site 0056)

    Allentown, Pennsylvania

  • University of Texas, Southwestern Medical Center ( Site 0015)

    Dallas, Texas

  • Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 7001)

    Salt Lake City, Utah

  • University of Vermont Medical Center ( Site 0001)

    Burlington, Vermont

  • Blue Ridge Cancer Care - Roanoke ( Site 0043)

    Roanoke, Virginia

  • Seattle Cancer Care Alliance-Renal/Melanoma/MCC ( Site 0093)

    Seattle, Washington

  • Central Washington Health Services Association d/b/a Confluence Health ( Site 0061)

    Wenatchee, Washington

  • Centro de Urología (CDU) ( Site 0803)

    CABA, Buenos Aires, Argentina

  • Hospital Británico de Buenos Aires-Oncology ( Site 0801)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Instituto Alexander Fleming ( Site 0800)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Asociación de Beneficencia Hospital Sirio Libanés ( Site 0804)

    Buenos Aires, Buenos Aires F.D., Argentina

  • Sanatorio Británico-Clinical Oncology Department ( Site 0802)

    Rosario, Santa Fe Province, Argentina

  • Sanatorio Parque ( Site 0806)

    Rosario, Santa Fe Province, Argentina

  • GenesisCare North Shore ( Site 4011)

    St Leonards, New South Wales, Australia

Showing 40 of 184 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.